Next, we evaluated the in vivo radioactivity distribution of [18F]FBNAF with or without coinjection of BP-1–102, an orally bioavailable and selective STAT3 inhibitor that binds to the SH2 domain of STAT3 (Zhang et al. 2012), as summarized in Fig. 5A. At 30 min after administration, the tumor radioactivity in the blocking group was significantly lower than that in the control group (1.0 ± 0.3% ID/g vs. 1.5 ± 0.1% ID/g, p < 0.05), whereas that in blood and muscle was negligibly affected by coinjection of the inhibitor. This evidence concerns the gene STAT3 and neoplasm.